NCT03331601View on ClinicalTrials.gov

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
CarcinomaReceptor, ErbB-2
Interventions
DRUG

68GaNOTA-Anti-HER2 VHH1

Injection of the radiopharmaceutical and PET/CT 90 min post injection

Trial Locations (1)

1090

RECRUITING

Uz Brussel, Brussels

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER